Marc M. Loriaux, M.D.
- click here
- 503 494-6775
Marc Loriaux, M.D., Ph.D. joined the Department of Pathology and Medicine in July, 2003 after completing a fellowship in Hematopathology at OHSU. He will help to staff the diagnostic hematopathology service and continue his research in Dr. Brian Druker’s laboratory studying tyrosine kinases as possible therapeutic targets in the treatment of hematologic malignancies.
"A case study of personalized therapy for osteosarcoma,"
"CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway,"
"Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-Î² and Src in tumor growth,"
"HitWalker: Variant prioritization for personalized functional cancer genomics,"
"The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias,"